Novanta（NOVT）株式概要
ノバンタ社は、その子会社とともに、精密医療、精密製造、医療ソリューション、ロボット工学および自動化ソリューション、高度外科手術ソリューションを米国内外で提供している。 詳細
NOVT Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Novanta Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$134.31 |
| 52週高値 | US$176.38 |
| 52週安値 | US$98.27 |
| ベータ | 1.68 |
| 1ヶ月の変化 | -7.53% |
| 3ヶ月変化 | -11.25% |
| 1年変化 | 18.67% |
| 3年間の変化 | -3.67% |
| 5年間の変化 | -18.37% |
| IPOからの変化 | 742.72% |
最新ニュース
Seeking Alpha • Aug 23
Novanta: A Strong Year So Far, Fully Priced In
Summary Novanta completed the Riverpoint Medical acquisition, enhancing recurring consumables and medical business growth prospects. Q2 sales rose 10% to $266M with 9% organic growth and adjusted EBITDA up 16%, reflecting strong operational performance. Forward guidance projects 2026 sales of $1.135B and adjusted earnings of $3.71 per share, with Riverpoint contributing $0.18-$0.25 EPS in 2027. Despite improved fundamentals and backlog, Novanta trades at a demanding 36-37x forward earnings, keeping risk-reward only modestly improved. Read the full article on Seeking Alpha
ナラティブ更新 • Aug 22
NOVT: Future Returns Will Depend On Executing Medical Acquisition And Restructuring Strategy
Analysts have lifted their price target on Novanta to $194.50 from $182, citing updated valuation work after Q2 results and the stock's inclusion on a conviction list as key supports for the new view. Analyst Commentary Recent research updates around Novanta highlight how analysts are thinking about the stock after the latest Q2 results and its inclusion on an analyst conviction list.ナラティブ更新 • Aug 08
NOVT: Future Returns Will Hinge On Executing Medical Acquisition And Restructuring Plans
Novanta's updated fair value estimate has increased from $175 to $182, reflecting analysts' higher price targets and refreshed models following recent earnings updates and the stock's addition to a conviction list. Analyst Commentary Recent Street research on Novanta points to a generally constructive view on the stock, with analysts updating their models after Q1 and Q2 results and after the company was added to an Analyst Conviction List.Recent updates
Seeking Alpha • Aug 23
Novanta: A Strong Year So Far, Fully Priced In
Summary Novanta completed the Riverpoint Medical acquisition, enhancing recurring consumables and medical business growth prospects. Q2 sales rose 10% to $266M with 9% organic growth and adjusted EBITDA up 16%, reflecting strong operational performance. Forward guidance projects 2026 sales of $1.135B and adjusted earnings of $3.71 per share, with Riverpoint contributing $0.18-$0.25 EPS in 2027. Despite improved fundamentals and backlog, Novanta trades at a demanding 36-37x forward earnings, keeping risk-reward only modestly improved. Read the full article on Seeking Alphaナラティブ更新 • Aug 22
NOVT: Future Returns Will Depend On Executing Medical Acquisition And Restructuring Strategy
Analysts have lifted their price target on Novanta to $194.50 from $182, citing updated valuation work after Q2 results and the stock's inclusion on a conviction list as key supports for the new view. Analyst Commentary Recent research updates around Novanta highlight how analysts are thinking about the stock after the latest Q2 results and its inclusion on an analyst conviction list.ナラティブ更新 • Aug 08
NOVT: Future Returns Will Hinge On Executing Medical Acquisition And Restructuring Plans
Novanta's updated fair value estimate has increased from $175 to $182, reflecting analysts' higher price targets and refreshed models following recent earnings updates and the stock's addition to a conviction list. Analyst Commentary Recent Street research on Novanta points to a generally constructive view on the stock, with analysts updating their models after Q1 and Q2 results and after the company was added to an Analyst Conviction List.ナラティブ更新 • Jun 17
NOVT: Future Earnings Power Will Rely On Executing Riverpoint Acquisition Strategy
Analysts have adjusted their fair value estimate for Novanta to $175.0 from $171.5, citing updated models that incorporate recent Q1 results, accelerating bookings and growth momentum, along with a revised future P/E assumption of 34.67x. Analyst Commentary Recent Street commentary on Novanta focuses on how the latest Q1 results and updated models feed into valuation, execution risk and future growth assumptions for the stock.ナラティブ更新 • Jun 02
NOVT: Future Earnings Power Will Rely On Sustaining Bookings Strength And Margin Execution
Analysts have lifted their fair value estimate for Novanta stock from $157 to about $171.50, citing updated models that reflect Q1 results with accelerating bookings and ongoing growth momentum. Analyst Commentary Bullish Takeaways Bullish analysts point to accelerating Q1 bookings as a key support for a higher fair value range, seeing healthier near term demand feeding into updated models.分析記事 • May 15
Novanta Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
It's been a pretty great week for Novanta Inc. ( NASDAQ:NOVT ) shareholders, with its shares surging 14% to US$156 in...ナラティブ更新 • Apr 19
NOVT: Future Earnings Power Will Rely On Executing Stronger Margins
Narrative update on Novanta The consensus analyst price target for Novanta has been raised by $12 to $150. Analysts cite updated models after Q4 results that indicate potential for stronger sales and margin performance.ナラティブ更新 • Apr 05
NOVT: Future Earnings Power Will Rely On Accelerating Sales And Margins
Analysts have trimmed their fair value estimate for Novanta from $160 to $157, reflecting a slightly higher discount rate and a modestly lower future P/E assumption, while still pointing to expectations for improving sales and margins after recent model updates. Analyst Commentary Bullish Takeaways Bullish analysts see room for the shares to move toward their updated fair value range, supported by model revisions that assume improving sales trends and margin recovery after recent results.ナラティブ更新 • Mar 22
NOVT: Future Earnings Power Will Rely On Accelerating Margins
Analysts have lifted their price target on Novanta to $150 from $138, citing updated Q4 models that suggest the company may be positioned for faster sales growth and margin expansion. Analyst Commentary Bullish Takeaways Bullish analysts point to the raised price target to $150 as a sign that updated Q4 assumptions support a higher valuation range for the shares.ナラティブ更新 • Mar 06
NOVT: Future Earnings Power Will Rely On Accelerating Margins
Analysts have lifted their fair value estimate for Novanta to $160 from $154, supported by updated models that reflect expectations for accelerating sales and margins following recent Q4 results and a higher Street price target of $150 from $138. Analyst Commentary Recent commentary points to a more constructive view on Novanta following its Q4 results, with updated models feeding into a higher fair value framework and a Street price target of $150.ナラティブ更新 • Feb 20
NOVT: Stable Outlook Will Rely On Steady Margins And Earnings Multiple
Narrative Update: Novanta Analyst Price Target The analyst price target for Novanta is unchanged at $154, as analysts keep their assumptions for fair value, discount rate, revenue growth, profit margin and future P/E essentially steady. Valuation Changes Fair Value: $154.00 remains effectively unchanged compared with the prior estimate of $154.ナラティブ更新 • Feb 06
NOVT: Equity Units Offering Will Support Balance Sheet And Future Deals
Analysts have nudged their price target on Novanta slightly higher to reflect modest tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions, framing the move as fine tuning rather than a major reset in expectations. What's in the News Novanta plans to look for acquisitions and investments, signaling an interest in adding to its portfolio of businesses (Key Developments).ナラティブ更新 • Jan 22
NOVT: Equity Units And Share Repurchases Will Support Balance Sheet And Future Deals
Analysts now keep their price target for Novanta effectively unchanged at about $154.00. They point to steady assumptions around discount rate, revenue growth, profit margin and future P/E as the key drivers of their view.ナラティブ更新 • Jan 08
NOVT: Equity Units Offering Will Strengthen Balance Sheet And Support Future Deals
Analysts have maintained their fair value estimate for Novanta at approximately $154. They cite only marginal adjustments to the discount rate, long term revenue growth, profit margin assumptions, and future P/E, which do not materially change their overall outlook.ナラティブ更新 • Dec 24
NOVT: New Equity Raise Will Strengthen Balance Sheet And Support Future Deals
Analysts have maintained their price target for Novanta at approximately $154 per share. This reflects a steady outlook, as incremental adjustments to discount rate assumptions and long term growth and profitability estimates are viewed as too minor to warrant a change in fair value.ナラティブ更新 • Dec 10
NOVT: Expanded Equity Offering And Buybacks Will Drive Long Term Shareholder Value
Analysts have nudged their price target for Novanta slightly higher to align with its updated fair value of $154.00, reflecting modestly stronger confidence in the company’s steady growth and margin profile. What's in the News Novanta completed a $550 million composite tangible equity units offering, issuing 11 million units priced at $50 each, with a $1.375 discount per unit (Key Developments).ナラティブ更新 • Nov 26
NOVT: Expanded Buyback Authorization Will Increase Shareholder Value Going Forward
Narrative Update on Novanta: Analyst Price Target Change Analysts have maintained Novanta's fair value estimate at $154. They cited improved profitability metrics, which offset slight adjustments in the discount rate and growth projections.ナラティブ更新 • Nov 10
NOVT: Equity Buyback Expansion And Profit Margin Gains Will Drive Upside
Analysts have raised their fair value estimate for Novanta from $141.50 to $154.00 per share, citing expectations for stronger future revenue growth and improved profit margins, even though the discount rate is slightly higher. What's in the News Novanta Inc.分析記事 • Oct 28
Novanta Inc. (NASDAQ:NOVT) Looks Just Right With A 30% Price Jump
Novanta Inc. ( NASDAQ:NOVT ) shares have had a really impressive month, gaining 30% after a shaky period beforehand...分析記事 • Oct 07
Is Now The Time To Look At Buying Novanta Inc. (NASDAQ:NOVT)?
Novanta Inc. ( NASDAQ:NOVT ), is not the largest company out there, but it received a lot of attention from a...ナラティブ更新 • Sep 05
Robotics And Healthcare Demand Will Expand Market Opportunities
Novanta’s fair value outlook remains unchanged, as both the discount rate and future P/E shifted only marginally, leaving the consensus analyst price target steady at $141.50. What's in the News Novanta projects third quarter 2025 GAAP revenue of $244 million to $247 million and full year 2025 GAAP revenue of $970 million to $985 million.Seeking Alpha • Apr 06
Novanta: A Trusted Yet Premium Technology Partner
Summary Novanta has shown solid growth over the past decade, but growth has been a bit sluggish in recent years. The company is a key technology partner for global OEMs, with balanced revenue from advanced industrial and medical applications, boasting strong EBITDA margins. Despite a recent acquisition and increased sales, competitive dynamics, and macroeconomic challenges have pressured growth; shares are now trading at a lower, yet still premium, multiple. With debt reduced and growth returning, shares deserve a premium, but need to fall below $100 for a more attractive valuation. Read the full article on Seeking AlphaSeeking Alpha • Jan 01
Novanta: Delayed Recovery And Prolonged Struggles Ahead, Downgrade To Sell
Summary Novanta's Q3 results show revenue growth but a decline in gross margin and shipment deferrals, indicating prolonged challenges. Macroeconomic pressures, including weak demand and high interest rates, are hindering recovery in the life sciences sector. The company's book-to-bill ratio below 1 signals weakening demand, and its high debt levels add to the risk. Novanta’s valuation is too high given its low growth prospects, especially compared to more promising peers. As a result of these factors, Novanta is downgraded from a hold to a sell, as its current price does not justify the risks. Read the full article on Seeking AlphaSeeking Alpha • Sep 02
Novanta Inc.: Overpriced In A Weak Demand Market. Here's Why It's A Hold
Summary Novanta Inc. is a leading tech provider facing macroeconomic headwinds and a soft demand climate, which have pressured its revenue and profitability. Despite strong fundamentals and a solid market position, its current high valuation makes it a risky investment. NOVT has managed modest revenue growth but struggles with significant inflationary challenges. For now, a Hold rating is recommended as the stock's valuation does not align with its performance amidst ongoing market uncertainties. Read the full article on Seeking Alpha
新しいナラティブ • Aug 28
Innovative Medical Devices And Tactical Acquisitions Poised To Accelerate Company Growth
Focusing on medical devices with new products might significantly boost future revenue through innovation, aiming for notable revenue from new launches by 2025.株主還元
| NOVT | US Electronic | US 市場 | |
|---|---|---|---|
| 7D | -4.1% | 2.2% | -0.1% |
| 1Y | 18.7% | 37.9% | 11.9% |
業界別リターン: NOVT過去 1 年間で37.9 % の収益を上げたUS Electronic業界を下回りました。
リターン対市場: NOVT過去 1 年間で11.9 % の収益を上げたUS市場を上回りました。
価格変動
| NOVT volatility | |
|---|---|
| NOVT Average Weekly Movement | 6.8% |
| Electronic Industry Average Movement | 9.0% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 2.9% |
安定した株価: NOVT 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: NOVTの 週次ボラティリティ ( 7% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1968 | 3,000 | Matthijs Glastra | www.novanta.com |
ノバンタ・インク（Novanta Inc.）は、その子会社とともに、精密医療、精密製造、医療ソリューション、ロボット工学およびオートメーション・ソリューション、先進手術ソリューションを米国内外で提供している。同社はオートメーション・イネーブリング・テクノロジーズ部門とメディカル・ソリューション部門を運営している。精密医療・製造部門では、レーザービームのステアリング・スキャニング・ソリューション、レーザー光源、ロボット・精密モーション、ロボット・エンド・オブ・アーム・ツーリング、ベアリング・スピンドルの設計・製造・販売を行っている。このセグメントでは、高度な産業プロセス、高度な産業用および医療用ロボット、その他の医療およびライフサイエンス自動化アプリケーション、眼科アプリケーションなどの医療用レーザー処置に対応している。メディカル・ソリューションズ部門は、医療用気腹器、ポンプ、関連ディスポーザブル、画像処理、識別、RFIDソリューション、高度モーションコントロールソリューション、ライトエンジン、統合手術室技術など、幅広い医療グレードの技術を提供している。同社は以前はGSI Group, Inc.として知られていたが、2016年5月に社名をNovanta Inc.に変更した。ノバンタ・インクは1968年に法人化され、マサチューセッツ州ベッドフォードに本社を置いている。
Novanta Inc. 基礎のまとめ
| NOVT 基礎統計学 | |
|---|---|
| 時価総額 | US$5.04b |
| 収益（TTM） | US$61.76m |
| 売上高(TTM) | US$1.03b |
82.2x
PER（株価収益率4.9x
P/SレシオNOVT は割高か？
公正価値と評価分析を参照収益と収入
| NOVT 損益計算書（TTM） | |
|---|---|
| 収益 | US$1.03b |
| 売上原価 | US$571.02m |
| 売上総利益 | US$458.68m |
| その他の費用 | US$396.91m |
| 収益 | US$61.76m |
直近の収益報告
Jul 03, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 1.63 |
| グロス・マージン | 44.54% |
| 純利益率 | 6.00% |
| 有利子負債／自己資本比率 | 14.2% |
NOVT の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/09/21 21:29 |
| 終値 | 2026/09/21 00:00 |
| 収益 | 2026/07/03 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Novanta Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8
| アナリスト | 機関 |
|---|---|
| Robert Mason | Baird |
| Quinn Fredrickson | Baird |
| Andrew Buscaglia | Berenberg |